国产一级a毛一级a看免费视频,久久久久久国产一级AV片,免费一级做a爰片久久毛片潮,国产精品女人精品久久久天天,99久久久无码国产精品免费了

產(chǎn)品推薦:氣相|液相|光譜|質(zhì)譜|電化學(xué)|元素分析|水分測(cè)定儀|樣品前處理|試驗(yàn)機(jī)|培養(yǎng)箱


化工儀器網(wǎng)>技術(shù)中心>行業(yè)標(biāo)準(zhǔn)>正文

歡迎聯(lián)系我

有什么可以幫您? 在線咨詢

Qiagen 試劑盒簡(jiǎn)介

來(lái)源:北京華夏遠(yuǎn)洋科技有限公司   2012年03月29日 14:28  

         Qiagen  品牌簡(jiǎn)介

          QIAGEN was founded 1984 as a spin-off at the University of Düsseldorf. Since then the company has continuously developed and turned into what is today the world's leading provider for innovative sample and assay technologies for research in molecular diagnostics, applied testing, pharma and academic research.

2011
  • QIAGEN acquires a strategic stake in Alacris Theranostics GmbH. The startup uses a novel approach to personalize cancer treatments;
    QIAGEN has an exclusive option to commercialize all biomarkers emerging from this research work.
2010
  • QIAGEN acquires a new detection technology for point of need applications in molecular diagnostics and applied testing. The instruments are highly affordable, portable and generate results in between 5 and 15 minutes.
  • This technology plays a key role in a pilot project run by the UN Food and Agriculture Organization and the International Atomic Energy Agency to contain animal diseases in emerging countries.
  • QIAGEN launches QIAsymphony RGQ, a modular automation platform covering entire laboratory workflows in molecular diagnostics. Its users have access to the broadest commercially available PCR test portfolio and can also run lab-developed tests.
2009
  • QIAGEN’s shares are included in the renowned NASDAQ-100 index.
  • QIAGEN enhances its portfolio with several PCR-based assay panels covering entire biological pathways and diseases, thereby strengthening its offering for pharmaceutical research.
  • QIAGEN acquires DxS Ltd., creating leadership in personalized healthcare. The combined company is active in more than 15 collaborations with pharmaceutical companies and markets 18 assays for companion diagnostics.
  • QIAGEN’s technologies play a key role in the fight against the global Swine Flu pandemic.
  • With the real-time PCR cycler Rotor-Gene Q and QIAgility for automated assay setup, QIAGEN enables the automation of complete laboratory workflows from sample to result.
2008
  • With Pyrosequencing, QIAGEN acquires a novel detection technology that works on a single base-pair level and thus even allows the identification of unknown DNA sequences or mutations.
  • QIAsymphony SP launches as the first system in a series of modular instruments, designed to automate entire laboratory workflows.
2007
  • QIAGEN merges with Digene Corp., creating the market and technology leader in molecular diagnostics.
  • QIAGEN introduces QIAcube, a revolutionary platform which fully automates the processing of QIAGEN consumable products.
2006
  • QIAGEN acquires a “Multiplexing” assay technology, which allows for the testing of multiple pathogens in one single run.
  • QIAGEN establishes its Asia regional headquarters in Shanghai.
2005
  • QIAGEN acquires a leading position in molecular diagnostics by adding various sets of PCR-based molecular tests to its portfolio.
  • Development of the artus influenza kit for the rapid detection of all known variants of the Avian Flu virus H5N1. The test reduces the time to result to 75 minutes.
  • QIAGEN receives world’s first governmental clearance for an Avian Flu assay (through its subsidiary PG Biotech in China).
  • QIAGEN launches the first human whole genome siRNA set worldwide. SiRNAs are RNA molecules that can reduce or shut down activity of individual genes for researchers to learn more about their function.
2004
  • QIAGEN’s QIAamp becomes the world’s first standalone product for sample preparation to receive the CE mark.
2002
  • QIAGEN relocates its US headquarters from Valencia, CA, to Germantown, MD.
2001
  • QIAGEN launches PAXgene, the first product that consolidates and integrates key steps of sample collection, stabilization and purification.
1999
  • PreAnalytiX, a joint venture with Becton, Dickinson and Company, is established.
1998
  • QIAGEN significantly expands its R&D and manufacturing capabilities in the automation business.
1997
  • Initial Public Offering is completed on Deutsche Boerse (Prime Standard), Frankfurt.
1996
  • QIAGEN N.V. (Holding) established in Venlo, The Netherlands.
  • Initial Public Offering is completed on NASDAQ, New York.
  • QIAGEN introduces the BioRobot 9600, its first benchtop workstation, which automates purification technologies.
1986
  • QIAGEN revolutionizes molecular biology by introducing the first “Plasmid-Kit.“ The discovery reduces the time needed for the preparation of plasmids, little ring-shaped DNA molecules of a bacteria’s cell, from 2-3 days to 2 hours.
1984
  • QIAGEN is founded in Duesseldorf, Germany.

免責(zé)聲明

  • 凡本網(wǎng)注明“來(lái)源:化工儀器網(wǎng)”的所有作品,均為浙江興旺寶明通網(wǎng)絡(luò)有限公司-化工儀器網(wǎng)合法擁有版權(quán)或有權(quán)使用的作品,未經(jīng)本網(wǎng)授權(quán)不得轉(zhuǎn)載、摘編或利用其它方式使用上述作品。已經(jīng)本網(wǎng)授權(quán)使用作品的,應(yīng)在授權(quán)范圍內(nèi)使用,并注明“來(lái)源:化工儀器網(wǎng)”。違反上述聲明者,本網(wǎng)將追究其相關(guān)法律責(zé)任。
  • 本網(wǎng)轉(zhuǎn)載并注明自其他來(lái)源(非化工儀器網(wǎng))的作品,目的在于傳遞更多信息,并不代表本網(wǎng)贊同其觀點(diǎn)和對(duì)其真實(shí)性負(fù)責(zé),不承擔(dān)此類作品侵權(quán)行為的直接責(zé)任及連帶責(zé)任。其他媒體、網(wǎng)站或個(gè)人從本網(wǎng)轉(zhuǎn)載時(shí),必須保留本網(wǎng)注明的作品第一來(lái)源,并自負(fù)版權(quán)等法律責(zé)任。
  • 如涉及作品內(nèi)容、版權(quán)等問(wèn)題,請(qǐng)?jiān)谧髌钒l(fā)表之日起一周內(nèi)與本網(wǎng)聯(lián)系,否則視為放棄相關(guān)權(quán)利。
企業(yè)未開(kāi)通此功能
詳詢客服 : 0571-87858618
主站蜘蛛池模板: 五寨县| 新泰市| 衡阳县| 海林市| 和田市| 宁乡县| 周至县| 班戈县| 广汉市| 塔河县| 仲巴县| 徐州市| 时尚| 嘉定区| 湟中县| 临湘市| 朝阳县| 迁西县| 精河县| 晋中市| 阜宁县| 绵阳市| 绥滨县| 大宁县| 家居| 衡南县| 白朗县| 武冈市| 新巴尔虎右旗| 双流县| 玉门市| 蒲江县| 旬邑县| 屯昌县| 牙克石市| 太仓市| 绵阳市| 巴中市| 启东市| 三江| 灌云县|